Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic heart failure

Initial treatment

Must be treated by a cardiologist; or

Must be treated by an authorised prescriber (medical practitioner, nurse practitioner) who has been directed to prescribe this medicine by a cardiologist; AND

Patient must be symptomatic with NYHA classes II, III or IV; AND

Patient must have a documented left ventricular ejection fraction (LVEF) of less than 45%; AND

The condition must be stabilised following a decompensation event that required at least one of: (i) hospitalisation in the past 6 months, (ii) intravenous diuretic therapy in the past three months; AND

Patient must not have clinical signs of fluid overload; AND

Patient must not have received intravenous treatment for fluid overload in the previous 24 hours; AND

Patient must not have a systolic blood pressure less than 100 mmHg; AND

The treatment must be an add-on therapy to optimal standard chronic heart failure treatment, which must include a beta-blocker, unless contraindicated according to the TGA-approved Product Information or cannot be tolerated; AND

The treatment must be an add-on therapy to optimal standard chronic heart failure treatment, which must include an ACE inhibitor, unless contraindicated according to the TGA-approved Product Information or cannot be tolerated; or

The treatment must be an add-on therapy to optimal standard chronic heart failure treatment, which must include an angiotensin II antagonist, unless contraindicated according to the TGA-approved Product Information or cannot be tolerated; or

The treatment must be an add-on therapy to optimal standard chronic heart failure treatment, which must include an angiotensin receptor with neprilysin inhibitor combination therapy unless contraindicated according to the TGA-approved Product Information or cannot be tolerated.